Drugs that contain Empagliflozin; Metformin Hydrochloride

1. List of Synjardy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Sep, 2030

(7 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's patent expiration?
More Information on Dosage

SYNJARDY family patents

20

European Union

19

United States

10

China

9

Japan

7

Argentina

7

Canada

6

Hong Kong

6

Korea, Republic of

6

Peru

5

Spain

5

Germany

5

Israel

4

RS

4

Australia

4

Poland

4

Uruguay

4

Cyprus

4

Mexico

4

Slovenia

4

Portugal

4

EA

4

Croatia

4

Norway

4

New Zealand

4

Taiwan, Province of China

4

Denmark

3

Austria

3

Brazil

3

Chile

3

Ukraine

3

Hungary

3

ME

2

Lithuania

2

Malaysia

2

South Africa

2

Ecuador

1

Morocco

1

AP

1

Luxembourg

1

Tunisia

1

Singapore

1

Turkey

1

Philippines

1

India

2. List of Synjardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

SYNJARDY XR family patents

22

United States

20

European Union

10

Japan

9

China

7

Argentina

7

Canada

6

Korea, Republic of

5

Hong Kong

5

Germany

5

Peru

4

Uruguay

4

Spain

4

Israel

4

Mexico

4

EA

4

Norway

4

New Zealand

3

Austria

3

RS

3

Brazil

3

Australia

3

Chile

3

Poland

3

Cyprus

3

Slovenia

3

Portugal

3

Croatia

3

Taiwan, Province of China

3

Denmark

2

Malaysia

2

Ukraine

2

Hungary

2

South Africa

2

Singapore

2

ME

1

Lithuania

1

Luxembourg

1

Turkey

1

Philippines

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic